Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
Authors:
- Taila HartleyTHTaila Hartley
- Luca CavalloneLCLuca Cavallone
- Nelly SabbaghianNSNelly Sabbaghian
- Rachel Silva-SmithRSRachel Silva-Smith
- Nancy HamelNHNancy Hamel
- Olga AleynikovaOAOlga Aleynikova
- Erika SmithESErika Smith
- Valerie HastingsVHValerie Hastings
- Pedro PintoPPPedro Pinto
- Marc TischkowitzMTMarc Tischkowitz
- Eva TomiakETEva Tomiak
- William D FoulkesWFWilliam D Foulkes
Open Access
- 28 August 2014
- journal article
- research article
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 12 (1) , 19
Abstract
PALB2 has emerged as a breast cancer susceptibility gene. Mutations in PALB2 have been identified in almost all breast cancer populations studied to date, but the rarity of these mutations and lack of information regarding their penetrance makes genetic counseling for these families challenging. We studied BRCA1/2 -negative breast and/or ovarian cancer families to a) assess the contribution of PALB2 mutations in this series and b) identify clinical, pathological and family history characteristics that might make PALB2 screening more efficient. The coding region of the PALB2 gene was analyzed in 175 probands with family histories of breast and/or ovarian cancer ascertained from a single Canadian institution in Eastern Ontario. We identified 2 probands with PALB2 mutations that are known or strongly considered to be pathogenic and 3 probands with missense mutations that are possibly pathogenic. One of the identified truncating mutations [c.3113G > A (p.Gly1000_Trp1038del – major product)], has been previously described while the other four mutations [c.3507_3508delTC (p.H1170Ffs*19), c.1846G > C (p.D616H), c.3418 T > G (p.W1140G), c.3287A > G (p.N1096S)] have not been previously reported. Loss of heterozygosity was detected in two breast tumors from one c.3507_3508delTC mutation carrier but not in other available tumors from that family or in tumors from carriers of other mutations. PALB2 mutation screening identifies a small, but significant number of mutations in BRCA1/2 -negative breast and/or ovarian cancer families. We show that mutations are more likely to be found in families with three or more breast cancers as well as other BRCA2-related cancers. In our cohort, both clearly pathogenic mutations were identified in premenopausal breast cancer cases (2/77, 2.6%). Testing should be preferentially offered to affected women from such families.Keywords
This publication has 33 references indexed in Scilit:
- Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?Journal of Clinical Oncology, 2013
- Prevalence of PALB2 mutations in Australasian multiple-case breast cancer familiesBreast Cancer Research, 2013
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Mutation analysis of the PALB2 cancer predisposition gene in familial melanomaFamilial Cancer, 2010
- PALB2: a novel inactivating mutation in a Italian breast cancer familyFamilial Cancer, 2010
- MutationTaster evaluates disease-causing potential of sequence alterationsNature Methods, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer familiesBreast Cancer Research and Treatment, 2008
- Analysis ofPALB2/FANCN-associated breast cancer familiesProceedings of the National Academy of Sciences, 2007
- PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneNature Genetics, 2006